medac is a future-oriented company and has been growing dynamically since fifty years. More than 1800 medac employees work on the first-time development and further refinement of pharmaceuticals and medical products for the diagnosis and treatment of oncological, urological and auto-immune diseases. Especially when it is a question of niche products we are one of the leading pharmaceutical companies. We represent solid values and basically think in human terms. This results in long-lasting business partnership relations with clinics, doctors and laboratories, as well as providing a healthy working atmosphere for all our employees
The experimental use of BCG-medac as a vaccine against COVID-19 is associated with a high risk of serious adverse reactions and should therefore be strictly avoided. The Federal Institute for Vaccines and Biomedical Medicines (Paul-Ehrlich Institut (PEI)) has published a respective safety information:
Cookie-Settings
We use cookies to give you the best experience possible with our website and to improve our communication with you. We consider your selection and will only use the data you have approved us to gather.
Necessary cookies
These cookies help making a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.
Statistics cookies
These cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously. With this information we can constantly improve the experience we offer on our website.
Marketing cookies
These cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.